Will Three Be The Charm For FDA Review Of Antipsychotics For Pediatric Use?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Psychopharmacologic Drugs Advisory Committee will evaluate pediatric indications for AstraZeneca’s Seroquel, Pfizer’s Geodon and Lilly’s Zyprexa during its June 9-10 meeting.
You may also be interested in...
Seroquel XR Needs Long-Term Safety Data For Depression, Anxiety Monotherapy – FDA Panel
AstraZeneca does gets recommendation for the atypical antipsychotic as adjunct therapy in major depressive disorder.
Risperdal Gets Approval For Adolescents; FDA Concerns Delay Zyprexa
Johnson & Johnson's Risperdal beat Lilly's Zyprexa as the first drug into the adolescent schizophrenia and bipolar I disorder market, with FDA approval for risperidone for the two indications Aug. 22
IFRA Hosts Capitol Hill Scent Experience In Timeout From Policy Concerns
The International Fragrance Association North America took a break from its higher-stakes advocacy work Nov. 1 to give lawmakers and congressional staffers a "scent experience." Perfumers from six of the group's biggest members were on hand with "Scents of Home," joined by Monell Center researchers to educate attendees on the mechanics of scent and the important role it plays in people's lives.